Literature DB >> 6331462

Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK, 421 (Enalapril) in captopril-intolerant patients.

C D Smith, R D Smith, J H Korn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6331462     DOI： 10.1002/art.1780270716

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  8 in total

1.  Successful treatment of scleroderma renal crisis with enalapril.

Authors:  S R Milsom; M G Nicholls
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

2.  Benign outcome of hypertensive renal crisis in scleroderma.

Authors:  M H Arnold; R Robinson
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

Review 3.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 5.  The scleroderma kidney: progress in risk factors, therapy, and prevention.

Authors:  Guillaume Bussone; Alice Bérezné; Vincent Pestre; Loïc Guillevin; Luc Mouthon
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

6.  Tolerability of long term therapy with enalapril maleate in patients resistant to other therapies and intolerant to captopril.

Authors:  E J Rucinska; R Small; W S Mulcahy; D L Snyder; P V Rodel; J E Rush; R D Smith; J F Walker; J D Irvin
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

7.  Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.

Authors:  B Santos Ramos; M J Piña Vera; E Carvajal Gragera; M Atienza Fernández
Journal:  Pharm World Sci       Date:  1993-10-15

8.  Captopril: 4 years of post marketing surveillance of all patients in New Zealand.

Authors:  I R Edwards; D M Coulter; D M Beasley; D MacIntosh
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.